A single 5g dose of psilocybin-containing mushrooms (Enigma strain) was associated with striking short-term functional improvements in an octogenarian with a decade-long history of advanced Alzheimer's disease, including the return of spontaneous speech, urinary continence, and independent movement. Psilocybin acts on serotonin 5-HT2A receptors to alter large-scale brain network dynamics and may promote structural neural plasticity, potentially making residual functional capa

Too long to read? Go for the highlights below. Analysis of 133 patent filings between 2019-2024 shows mushroom-derived compounds targeting 14 therapeutic areas, with anticancer applications representing the largest cluster at 24 patents Ganoderma and Phellinus genera feature most prominently across filings, with Korea (43 patents), China (39), and the USA (27) leading global patenting activity Global medicinal mushroom market projected to reach $59.41 billion by 2031 at 8.2%

The nation’s first regulated psilocybin market shows promise but faces hurdles in accessibility and cost. In 2020, Oregon became the...

Compass Pathways has become the first company to publish Phase 3 data for a classical psychedelic. Its synthetic psilocybin candidate,...

With the rise of companies exploring psilocybin based drugs to treat various mental health conditions, the need for greater evidence...